GlobeNewswire by notified

Ultimovacs ASA - Private placement of new shares successfully placed

Share

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA, SOUTH AFRICA, NEW ZEALAND, JAPAN OR THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL

Ultimovacs ASA - Private placement of new shares successfully placed

Reference is made to the stock exchange announcement by Ultimovacs ASA (OSE: ULTI) ("Ultimovacs” or the "Company") on 26 October 2021 regarding the contemplated private placement of new shares (the "Offer Shares") of approximately NOK 225 to 270 million (the "Private Placement"). The Company hereby announces that it has allocated 2,160,000 new shares in the Private Placement at a subscription price of NOK 125 per share, raising gross proceeds of NOK 270 million. ABG Sundal Collier ASA, Carnegie AS and DNB Markets, a part of DNB Bank ASA are acting as joint bookrunners (the “Joint Bookrunners”) in connection with the Private Placement.

The net proceeds of the Private Placement will be used for (i) financing of the LUNGVAC Phase II trial evaluating UV1 in non-small cell lung cancer (“NSCLC”), (ii) bringing the UV1 platform into Phase III readiness, (iii) further development of the Tetanus-Epitope-Targeting (“TET”) technology platform, and (iv) general corporate purposes.

Notification of allotment of the Offer Shares including settlement instructions will be sent to the applicants through a notification from the Joint Bookrunners on 27 October 2021.

The Offer Shares allocated in the Private Placement are expected to be settled through a delivery versus payment transaction by delivery of existing and unencumbered shares in the Company that are already listed on Oslo Børs, pursuant to a share lending agreement between the Company, Gjelsten Holding AS and the Joint Bookrunners. The Offer Shares will thus be tradable from allocation. The Joint Bookrunners will settle the share loan with a corresponding number of new shares in the Company which has been resolved issued by the Board pursuant to the authorisation granted at the Company's annual general meeting on 15 April 2021.

Following registration of the new share capital pertaining to the Private Placement, the Company will have a share capital of NOK 3,422,176.10 divided into 34,221,761 shares, each with a par value of NOK 0.10.

The Company has considered the Private Placement in light of the equal treatment obligations under the Norwegian Securities Trading Act and the rules on equal treatment under Oslo Rule Book II for companies listed on the Oslo Stock Exchange and the Oslo Stock Exchange's Guidelines on the rule of equal treatment, and the Board is of the opinion that the contemplated transaction is in compliance with these requirements and guidelines. Taking into consideration the time, costs and expected terms of alternative methods of the securing the desired funding, the Board has concluded that offering new shares in a private placement on acceptable terms at this time is in the common interest of the shareholders of the Company. The Company will not conduct a subsequent repair offering.

Advokatfirmaet Schjødt AS is acting as legal advisor to the Company in connection with the Private Placement and Advokatfirmaet Wiersholm AS is acting as legal advisor to the Joint Bookrunners in connection with the Private Placement.

For additional information, please contact:

Carlos de Sousa, Chief Executive Officer
Email: carlos.desousa@ultimovacs.com
Phone: +47 908 92 507

Hans Vassgård Eid, Chief Financial Officer
Email: hans.eid@ultimovacs.com
Phone: +47 482 48 632

About Ultimovacs
Ultimovacs is developing immune-stimulatory vaccines to treat a broad range of cancers. Ultimovacs’ lead universal cancer vaccine candidate UV1 targets human telomerase (hTERT), present in 85-90% of cancers in all stages of tumor growth. By directing the immune system to hTERT antigens, UV1 drives CD4 helper T cells to the tumor to activate an immune system cascade and increase anti-tumor responses. With a broad Phase II program, Ultimovacs aims to clinically demonstrate UV1’s impact in multiple cancer types in combination with other immunotherapies. Ultimovacs’ second technology approach, based on the proprietary Tetanus-Epitope-Targeting (TET) platform, combines tumor-specific peptides and adjuvant in the same molecule and entered Phase I trials in 2021.

Important Notices

This announcement is not and does not form a part of any offer to sell, or a solicitation of an offer to purchase, any securities of the Company. The distribution of this announcement and other information may be restricted by law in certain jurisdictions. Copies of this announcement are not being made and may not be distributed or sent into any jurisdiction in which such distribution would be unlawful or would require registration or other measures. Persons into whose possession this announcement or such other information should come are required to inform themselves about and to observe any such restrictions.

The securities referred to in this announcement have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and accordingly may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and in accordance with applicable U.S. state securities laws. The Company does not intend to register any part of the offering or their securities in the United States or to conduct a public offering of securities in the United States. Any sale in the United States of the securities mentioned in this announcement will be made solely to "qualified institutional buyers" as defined in Rule 144A under the Securities Act.

In any EEA Member State, this communication is only addressed to and is only directed at qualified investors in that Member State within the meaning of the Prospectus Regulation, i.e., only to investors who can receive the offer without an approved prospectus in such EEA Member State. The expression "Prospectus Regulation" means Regulation 2017/1129 as amended together with any applicable implementing measures in any Member State.

This communication is only being distributed to and is only directed at persons in the United Kingdom that are (i) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order") or (ii) high net worth entities, and other persons to whom this announcement may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as "relevant persons"). This communication must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this communication relates is available only for relevant persons and will be engaged in only with relevant persons. Persons distributing this communication must satisfy themselves that it is lawful to do so.

Matters discussed in this announcement may constitute forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as "believe", "expect", "anticipate", "strategy", "intends", "estimate", "will", "may", "continue", "should" and similar expressions. The forward-looking statements in this release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors which are difficult or impossible to predict and are beyond its control.

Actual events may differ significantly from any anticipated development due to a number of factors, including without limitation, changes in investment levels and need for the Company’s services, changes in the general economic, political and market conditions in the markets in which the Company operate, the Company’s ability to attract, retain and motivate qualified personnel, changes in the Company’s ability to engage in commercially acceptable acquisitions and strategic investments, and changes in laws and regulation and the potential impact of legal proceedings and actions. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The Company does not provide any guarantees that the assumptions underlying the forward-looking statements in this announcement are free from errors nor does it accept any responsibility for the future accuracy of the opinions expressed in this announcement or any obligation to update or revise the statements in this announcement to reflect subsequent events. You should not place undue reliance on the forward-looking statements in this document.

The information, opinions and forward-looking statements contained in this announcement speak only as at its date, and are subject to change without notice. The Company does not undertake any obligation to review, update, confirm, or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this announcement.

Neither of the Joint Bookrunners nor any of their respective affiliates makes any representation as to the accuracy or completeness of this announcement and none of them accepts any responsibility for the contents of this announcement or any matters referred to herein.

This announcement is for information purposes only and is not to be relied upon in substitution for the exercise of independent judgment. It is not intended as investment advice and under no circumstances is it to be used or considered as an offer to sell, or a solicitation of an offer to buy any securities or a recommendation to buy or sell any securities in the Company. Neither the Joint Bookrunners nor any of their respective affiliates accepts any liability arising from the use of this announcement.

This information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements pursuant to section 5-12 the Norwegian Securities Trading Act.

This stock exchange announcement was published by Hans Vassgård Eid, CFO at Ultimovacs ASA on 27 October 2021 at 0:05 CEST on behalf of the Company.

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

JLT Mobile Computers acquires French sales partner ID Work8.12.2021 23:30:00 CET | Press release

With an own sales office JLT strengthens its local presence in the French market, which has grown to become one of the largest and most important regionsin Europe for JLT Växjö, Sweden, 8Dec2021 * * * JLT Mobile Computers, a leading supplier of reliable computers for demanding environments, today announced that they have signed the agreement to acquire of ID Work, their French sales partner with effect from January 2022. Since its start in 2013 ID Work has successfully been driving sales in France through a country-wide network consisting of system integrators and resellers. Since then, the French market has grown to become one of JLT’s largest and most important markets in Europe. JLT will be taking over the business and establish a local sales office with own personnel. Through the acquisition JLT will get closer to its customers and sales partners in France. The founder of ID Work, who is running the company today will have a continued involvement in JLT over the next couple of year

JLT Mobile Computers förvärvar sin franska säljpartner ID Work8.12.2021 23:30:00 CET | Pressemelding

Frankrike är ett av de största och viktigaste länderna i Europa för JLT ochsyftet med förvärvet är att etablera ett säljkontori egen regi för att stärkaden lokala närvaron Växjö, Sverige, 8:e december2021 * * * JLT Mobile Computers, ledande leverantör av stryktåliga datorer för krävande miljöer, annonserar idag att man har tecknat ett avtal om förvärv av sin franska säljpartner ID Work med tillträde i januari 2022. Sedan starten 2013 har ID Work framgångsrikt drivit försäljningen av JLT:s produkter i Frankrike genom ett landstäckande nätverk bestående av systemintegratörer och återförsäljare. Den franska marknaden har sedan dess vuxit till att bli en av JLT:s största och viktigaste marknader i Europa. JLT kommer att ta över ID Works verksamhet och etablera ett säljkontor med egen personal. Förvärvet gör att JLT kommer närmare sina kunder och säljpartners. Grundaren av ID Work som idag driver företaget kommer att ha ett fortsatt engagemang i JLT under de kommande åren. För mer informati

Better Collective initiates share buyback program to cover future payments relating to completed acquisitions and incentive programs8.12.2021 18:00:00 CET | Press release

Regulatory Release no. 38/2021 December 8, 2021 Better Collective A/S (the “Company”) has today initiated a share buyback program for up to 10 mEUR, to be executed during the period from December 9, 2021 to February 24, 2022. The purpose of the buyback program is to cover future payments relating to completed acquisitions and to cover established Incentive Plans. The buyback program is being initiated pursuant to the authorization granted by the shareholders at the annual general meeting held on April 26, 2021 to repurchase up to nominal 4,694,532 shares of EUR 0,01 each of the Company’s share capital in the period until the annual general meeting in 2022. The Company has appointed Nordea as lead manager of the buyback program. Under the agreement with Nordea, Nordea will purchase shares on behalf of the Company and will make its trading decisions independently of, and without influence by the Company. The buyback program is subject to the following terms: The purpose of the program is

Nextensa Nv/sa: Shares Repurchase8.12.2021 17:40:00 CET | Press release

NEXTENSA NV/SA: SHARES REPURCHASE Nextensa NV announces that the board of directors has decided to initiate a share repurchase programme to acquire up to 65,000 shares for a total amount of no more than 4,800,000 euros within the limits set down in the (renewed) share repurchase authorization as granted by the extraordinary general meeting of shareholders of 19 July 2021. The goal of the share repurchase is to enable Nextensa to meet its obligations resulting from the purchase plans for the benefit of its executive management. Nextensa recognizes the need for active and committed managers that are able to guide the transformation into a mixed property investor and developer. Furthermore, based on previous experience and current market practices and trends, the nomination and remuneration committee and the board of directors are convinced that managers are more engaged and committed when they are able to participate in the capital of Extensa NV, as this aligns their interests with those

Millicom files standard form for notification of major holdings8.12.2021 17:13:53 CET | Press release

Millicom files standard form for notification of major holdings Luxembourg,December 8, 2021 – Millicom International Cellular S.A. announced today the CSSF regulatory filing of the form: ANNEX A: Standard form for notification of major holdings (attachment) -END- For further information, please contact Press: Vivian Kobeh, Director Corporate Communications +1-786-628-5300 press@millicom.com Yocasta Valdez, Group Manager Digital Media & Communications +1-305-929-5417 press@millicom.com Investors: Michel Morin, VP Investor Relations +1-786-628-5270 investors@millicom.com Sarah Inmon, Director Investor Relations +1-786-628-5303 investors@millicom.com About Millicom Millicom (NASDAQ U.S.: TIGO, Nasdaq Stockholm: TIGO_SDB) is a leading provider of fixed and mobile services dedicated to emerging markets in Latin America and Africa. Millicom sets the pace when it comes to providing high-speed broadband and innovation around The Digital Lifestyle® services through its principal brand, TIGO. As

Volta Finance Limited - Result of AGM8.12.2021 16:04:30 CET | Press release

8 December 2021 Volta Finance Limited (VTA / VTAS) RESULTS OF THE FIFTEENTH ANNUAL GENERAL MEETING Volta Finance Limited announces that at the Fifteenth Annual General Meeting held earlier today all resolutions proposed were duly passed. One of these resolutions was a special resolution. The full text of the resolutions can be found in the Notice of Meeting contained within the Annual Report and Accounts 2021, copies of which are available for viewing on the Company’s website http://www.voltafinance.com. Further information on the votes cast for each resolution will be available on the Company’s website shortly. CONTACTS For the Investment Manager AXA Investment Managers Paris Serge Demay serge.demay@axa-im.com +33 (0) 1 44 45 84 47 Company Secretary and Administrator BNP Paribas Securities Services S.C.A, Guernsey Branch guernsey.bp2s.volta.cosec@bnpparibas.com +44 (0) 1481 750 853 Corporate Broker Cenkos Securities plc Andrew Worne Daniel Balabanoff +44 (0) 20 7397 8900 ***** ABOUT V

New Kisqali® data shows consistent overall survival benefit across genomic and clinical subtypes of interest in HR+/HER2- metastatic breast cancer8.12.2021 15:30:00 CET | Press release

Data from the MONALEESA Phase III program provide further evidence of the unique profile of Kisqali, the CDK4/6 inhibitor with the longest reported median overall survival (OS) in HR+/HER2- metastatic breast cancer (over 5 years) and proven OS benefit across patient subgroups1-5 Kisqali pooled data at the San Antonio Breast Cancer Symposium confirms OS benefit across most common genomic intrinsic subtypes of HR+/HER2- metastatic breast cancer, including the aggressive, ET-resistant HER2-enriched subtype6 Data supports rationale for HARMONIA, the first prospective, head-to-head Phase III trial seeking to identify the best therapeutic option between Kisqali and Ibrance®* for patients with the HER2-enriched subtype Kisqali remains the only CDK4/6i with consistent OS benefit across the entire MONALEESA program, regardless of site and number of metastases, prior treatment, endocrine partner, line of therapy or menopausal status1-5,7-8 Basel, December 8, 2021 — Novartis today announced new K